GMI-1070, a novel pan-selectin antagonist, reverses acute vascular occlusions in sickle cell mice.

Leukocyte adhesion in the microvasculature influences blood rheology and plays a key role in vaso-occlusive manifestations of sickle cell disease. Notably, polymorphonuclear neutrophils (PMNs) can capture circulating sickle red blood cells (sRBCs) in inflamed venules, leading to critical reduction in blood flow and vaso-occlusion. Recent studies have suggested that E-selectin expression by endothelial cells plays a key role by sending activating signals that lead to the activation of Mac-1 at the leading edge of PMNs, thereby allowing RBC capture. Thus, the inhibition of E-selectin may represent a valuable target in this disease. Here, we have tested the biologic properties of a novel synthetic pan-selectin inhibitor, GMI-1070, with in vitro assays and in a humanized model of sickle cell vaso-occlusion analyzed by intravital microscopy. We have found that GMI-1070 predominantly inhibited E-selectin-mediated adhesion and dramatically inhibited sRBC-leukocyte interactions, leading to improved microcirculatory blood flow and improved survival. These results suggest that GMI-1070 may represent a valuable novel therapeutic intervention for acute sickle cell crises that should be further evaluated in a clinical trial.

[1]  Beat Ernst,et al.  From carbohydrate leads to glycomimetic drugs , 2009, Nature Reviews Drug Discovery.

[2]  P. Frenette,et al.  HETEROTYPIC INTERACTIONS ENABLED BY POLARIZED NEUTROPHIL MICRODOMAINS MEDIATE THROMBO-INFLAMMATORY INJURY , 2009, Nature Medicine.

[3]  M. Steinberg.  Genetic Etiologies for Phenotypic Diversity in Sickle Cell Anemia , 2009, TheScientificWorldJournal.

[4]  D. Wagner,et al.  The vessel wall and its interactions. , 2008, Blood.

[5]  P. Frenette,et al.  Intravenous immunoglobulins reverse acute vaso-occlusive crises in sickle cell mice through rapid inhibition of neutrophil adhesion. , 2007, Blood.

[6]  S. Barthel,et al.  Targeting selectins and selectin ligands in inflammation and cancer , 2007, Expert opinion on therapeutic targets.

[7]  P. Frenette,et al.  Sickle cell disease: old discoveries, new concepts, and future promise. , 2007, The Journal of clinical investigation.

[8]  M. Gladwin,et al.  Levels of soluble endothelium‐derived adhesion molecules in patients with sickle cell disease are associated with pulmonary hypertension, organ dysfunction, and mortality , 2005, British journal of haematology.

[9]  John C Bischof,et al.  Critical role of endothelial cell activation in hypoxia-induced vasoocclusion in transgenic sickle mice. , 2005, American journal of physiology. Heart and circulatory physiology.

[10]  P. Frenette,et al.  Sickle cell vaso-occlusion. , 1991, Hematology/oncology clinics of North America.

[11]  R. Nagel,et al.  Sickle-cell disease , 2004, The Lancet.

[12]  R. Kannagi,et al.  Carbohydrate‐mediated cell adhesion in cancer metastasis and angiogenesis , 2004, Cancer science.

[13]  G. Vercellotti,et al.  Anti-inflammatory therapy ameliorates leukocyte adhesion and microvascular flow abnormalities in transgenic sickle mice. , 2004, American journal of physiology. Heart and circulatory physiology.

[14]  R. Nagel,et al.  Sickle-cell disease. , 2004, Lancet.

[15]  B. Ernst,et al.  Epitope mapping of sialyl Lewis(x) bound to E-selectin using saturation transfer difference NMR experiments. , 2003, Glycobiology.

[16]  K. Ley.  The role of selectins in inflammation and disease. , 2003, Trends in molecular medicine.

[17]  H. Gollnick,et al.  Efomycine M, a new specific inhibitor of selectin, impairs leukocyte adhesion and alleviates cutaneous inflammation , 2002, Nature Medicine.

[18]  B. Coller,et al.  Primary role for adherent leukocytes in sickle cell vascular occlusion: A new paradigm , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[19]  W. Jahnke,et al.  Preorganization of the Bioactive Conformation of Sialyl Lewis(X) Analogues Correlates with Their Affinity to E-Selectin. , 2001, Angewandte Chemie.

[20]  K. Kerr,et al.  The use of cylexin (CY-1503) in prevention of reperfusion lung injury in patients undergoing pulmonary thromboendarterectomy. , 2000, American journal of respiratory and critical care medicine.

[21]  R. Hynes,et al.  Multiple, targeted deficiencies in selectins reveal a predominant role for P-selectin in leukocyte recruitment. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[22]  R. Dixon,et al.  Novel synthetic inhibitors of selectin-mediated cell adhesion: synthesis of 1,6-bis[3-(3-carboxymethylphenyl)-4-(2-alpha-D- mannopyranosyloxy)phenyl]hexane (TBC1269). , 1998, Journal of medicinal chemistry.

[23]  E. Rubin,et al.  Transgenic knockout mice with exclusively human sickle hemoglobin and sickle cell disease. , 1997, Science.

[24]  T. Townes,et al.  Knockout-transgenic mouse model of sickle cell disease. , 1997, Science.

[25]  J. Brisson,et al.  Application of homonuclear 3D NMR experiments and 1D analogs to study the conformation of sialyl Lewisx bound to E-selectin , 1997, Journal of biomolecular NMR.

[26]  E. Kunkel,et al.  Distinct phenotype of E-selectin-deficient mice. E-selectin is required for slow leukocyte rolling in vivo. , 1996, Circulation research.

[27]  A. Beaudet,et al.  Infectious susceptibility and severe deficiency of leukocyte rolling and recruitment in E-selectin and P-selectin double mutant mice , 1996, The Journal of experimental medicine.

[28]  Richard O Hynes,et al.  Susceptibility to Infection and Altered Hematopoiesis in Mice Deficient in Both P- and E-Selectins , 1996, Cell.

[29]  Rm,et al.  Sickle cell disease , 1996 .

[30]  Richard D. Cummings,et al.  Tyrosine Sulfation of P-selectin Glycoprotein Ligand-1 Is Required for High Affinity Binding to P-selectin (*) , 1995, The Journal of Biological Chemistry.

[31]  S. Hemmerich,et al.  Sulfation-dependent recognition of high endothelial venules (HEV)- ligands by L-selectin and MECA 79, and adhesion-blocking monoclonal antibody , 1994, The Journal of experimental medicine.

[32]  G. Rodgers,et al.  Mortality in sickle cell disease. , 1994 .

[33]  O. Platt,et al.  Mortality in sickle cell disease. Life expectancy and risk factors for early death. , 1994, The New England journal of medicine.

[34]  F. Gaeta,et al.  ELAM-1 mediates cell adhesion by recognition of a carbohydrate ligand, sialyl-Lex. , 1990, Science.